COLUMBUS, Ohio – Three surgical oncology specialists in urology have joined the James Cancer Hospital and Solove Research Institute at The Ohio State University. Their diverse and innovative surgical skills bring a new dimension to Ohio State’s expanding capabilities in treating urologic cancers and other urologic disorders.
Drs. Ronney Abaza (43017), Ahmad Shabsigh (43017) and David Sharp (43221) bring with them skills and experience that will contribute greatly to the growing urologic oncology program at The James, according to Dr. Michael Caligiuri, CEO of The James and director of The Ohio State University Comprehensive Cancer Center.
“In addition, their expertise in urologic robotic procedures will help us expand our robotics program and answer a growing consumer demand for less invasive surgical treatments,” says Caligiuri.
Prostate cancer is the most common cancer, and the second most fatal cancer, in men. Nearly one in seven men risk developing prostate cancer in their lifetime, however, the five-year survival rate has increased from 69 percent in the 1970s to nearly 98 percent today.
By expanding its surgical staff, The James can offer patients a wide variety of treatment options and the highest level of expertise.
Abaza completed his medical degree at Northwestern University and came to The James from the University of Toledo to serve as the new director of robotic urologic surgery. Abaza has trained medical students, residents and fellow surgeons in laparoscopy and robotics and founded RoMIUS, the Robotic & Minimally-Invasive Urologic Institute of Northwest Ohio. At The James, he leads an experienced team of individuals dedicated to patients undergoing robotic surgery for the treatment of urologic conditions such as prostate, kidney and bladder cancers. Ohio State was one of the nation’s first hospitals to utilize robotics for minimally invasive surgical procedures, and Abaza has the expertise to be able to offer patients robotic surgical options that other hospitals currently cannot.
Shabsigh completed his residency at Columbia-Presbyterian Medical Center in New York and recently came from Memorial Sloan-Kettering Cancer Center in New York City, where he completed his fellowship. His clinical interests emphasize a balanced and multimodality approach for the treatment and cure of genitourinary malignancies. Shabsigh’s interests also include translational research, bridging the gap between research and clinical practice.
Sharp completed his medical degree at Baylor in Houston and his residency at the Cleveland Clinic. Sharp came to The James from Memorial Sloan-Kettering Cancer Center in New York City, where he was trained in the latest laparoscopic and robotic techniques for treating urologic cancers. He specializes in surgery for renal tumors and nerve-sparing surgery for prostate cancer. Sharp’s research interests include improving surgical outcomes and minimizing treatment-related morbidity for patients with kidney, prostate, testicular and bladder cancers # # #
Medical Center Communications